Yuankai Shi, Jian Fang, Xuezhi Hao, Shucai Zhang, Yunpeng Liu, Lin Wang, Jianhua Chen, Yi Hu, Xiaosheng Hang, Juan Li, Chunling Liu, Yiping Zhang, Zhehai Wang, Yanping Hu, Kangsheng Gu, Jian'an Huang, Liangming Zhang, Jinlu Shan, Weiwei Ouyang, Yanqiu Zhao, Wu Zhuang, Yan Yu, Jun Zhao, Helong Zhang, Pei Lu, Weidong Li, Meimei Si, Mingjing Ge, Huaize Geng. Signal Transduct Target Ther 2022
Times Cited: 1
Times Cited: 1
Times Cited
Times Co-cited
Similarity
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
100
The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis.
Shasha Wang, Rongrong Luo, Yuankai Shi, Xiaohong Han. Future Oncol 2022
Shasha Wang, Rongrong Luo, Yuankai Shi, Xiaohong Han. Future Oncol 2022
100
Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
Samantha Wilkinson, Alind Gupta, Nicolas Scheuer, Eric Mackay, Paul Arora, Kristian Thorlund, Radek Wasiak, Joshua Ray, Sreeram Ramagopalan, Vivek Subbiah. JAMA Netw Open 2021
Samantha Wilkinson, Alind Gupta, Nicolas Scheuer, Eric Mackay, Paul Arora, Kristian Thorlund, Radek Wasiak, Joshua Ray, Sreeram Ramagopalan, Vivek Subbiah. JAMA Netw Open 2021
100
Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
Jeng-Sen Tseng, Tsung-Ying Yang, Chih-Ying Wu, Wen-Hui Ku, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang. J Immunother 2018
Jeng-Sen Tseng, Tsung-Ying Yang, Chih-Ying Wu, Wen-Hui Ku, Kun-Chieh Chen, Kuo-Hsuan Hsu, Yen-Hsiang Huang, Kang-Yi Su, Sung-Liang Yu, Gee-Chen Chang. J Immunother 2018
100
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li,[...]. J Clin Oncol 2019
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li,[...]. J Clin Oncol 2019
100
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
Y-L Wu, D Planchard, S Lu, H Sun, N Yamamoto, D-W Kim, D S W Tan, J C-H Yang, M Azrif, T Mitsudomi,[...]. Ann Oncol 2019
Y-L Wu, D Planchard, S Lu, H Sun, N Yamamoto, D-W Kim, D S W Tan, J C-H Yang, M Azrif, T Mitsudomi,[...]. Ann Oncol 2019
100
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen,[...]. Cancer Discov 2018
100
First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: Clinical and designing strategy update of lorlatinib.
Sulman Basit, Zaman Ashraf, Kwangho Lee, Muhammad Latif. Eur J Med Chem 2017
Sulman Basit, Zaman Ashraf, Kwangho Lee, Muhammad Latif. Eur J Med Chem 2017
100
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, Harry J M Groen, Heather Wakelee, Toyoaki Hida, Tony Mok, David Spigel, Enriqueta Felip, Makoto Nishio,[...]. J Clin Oncol 2016
Lucio Crinò, Myung-Ju Ahn, Filippo De Marinis, Harry J M Groen, Heather Wakelee, Toyoaki Hida, Tony Mok, David Spigel, Enriqueta Felip, Makoto Nishio,[...]. J Clin Oncol 2016
100
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Chengwei Zhang, Xiao-Ran Han, Xiaobao Yang, Biao Jiang, Jing Liu, Yue Xiong, Jian Jin. Eur J Med Chem 2018
Chengwei Zhang, Xiao-Ran Han, Xiaobao Yang, Biao Jiang, Jing Liu, Yue Xiong, Jian Jin. Eur J Med Chem 2018
100
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura,[...]. Lancet 2017
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura,[...]. Lancet 2017
100
Structure and energy based quantitative missense variant effect analysis provides insights into drug resistance mechanisms of anaplastic lymphoma kinase mutations.
Jianzong Li, Yue Huang, Miaomiao Wu, Chuanfang Wu, Xin Li, Jinku Bao. Sci Rep 2018
Jianzong Li, Yue Huang, Miaomiao Wu, Chuanfang Wu, Xin Li, Jinku Bao. Sci Rep 2018
100
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).
Chelsea E Powell, Yang Gao, Li Tan, Katherine A Donovan, Radosław P Nowak, Amanda Loehr, Magda Bahcall, Eric S Fischer, Pasi A Jänne, Rani E George,[...]. J Med Chem 2018
Chelsea E Powell, Yang Gao, Li Tan, Katherine A Donovan, Radosław P Nowak, Amanda Loehr, Magda Bahcall, Eric S Fischer, Pasi A Jänne, Rani E George,[...]. J Med Chem 2018
100
Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib.
Gregory N Gan, Andrew J Weickhardt, Benjamin Scheier, Robert C Doebele, Laurie E Gaspar, Brian D Kavanagh, D Ross Camidge. Int J Radiat Oncol Biol Phys 2014
Gregory N Gan, Andrew J Weickhardt, Benjamin Scheier, Robert C Doebele, Laurie E Gaspar, Brian D Kavanagh, D Ross Camidge. Int J Radiat Oncol Biol Phys 2014
100
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta,[...]. N Engl J Med 2010
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta,[...]. N Engl J Med 2010
100
Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
Fausto Petrelli, Chiara Lazzari, Raffaele Ardito, Karen Borgonovo, Alessandra Bulotta, Barbara Conti, Mary Cabiddu, Jody Filippo Capitanio, Matteo Brighenti, Mara Ghilardi,[...]. PLoS One 2018
Fausto Petrelli, Chiara Lazzari, Raffaele Ardito, Karen Borgonovo, Alessandra Bulotta, Barbara Conti, Mary Cabiddu, Jody Filippo Capitanio, Matteo Brighenti, Mara Ghilardi,[...]. PLoS One 2018
100
Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer.
Dexter P Mendoza, Jessica J Lin, Marguerite M Rooney, Tianqi Chen, Lecia V Sequist, Alice T Shaw, Subba R Digumarthy. AJR Am J Roentgenol 2020
Dexter P Mendoza, Jessica J Lin, Marguerite M Rooney, Tianqi Chen, Lecia V Sequist, Alice T Shaw, Subba R Digumarthy. AJR Am J Roentgenol 2020
100
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
Chung Hyo Kang, Dong Ho Lee, Chong Ock Lee, Jae Du Ha, Chi Hoon Park, Jong Yeon Hwang. Biochem Biophys Res Commun 2018
Chung Hyo Kang, Dong Ho Lee, Chong Ock Lee, Jae Du Ha, Chi Hoon Park, Jong Yeon Hwang. Biochem Biophys Res Commun 2018
100
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao,[...]. Target Oncol 2019
Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao,[...]. Target Oncol 2019
100
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
Maria Menichincheri, Elena Ardini, Paola Magnaghi, Nilla Avanzi, Patrizia Banfi, Roberto Bossi, Laura Buffa, Giulia Canevari, Lucio Ceriani, Maristella Colombo,[...]. J Med Chem 2016
100
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Hiroyuki Yasuda, Lorena L de Figueiredo-Pontes, Susumu Kobayashi, Daniel B Costa. J Thorac Oncol 2012
Hiroyuki Yasuda, Lorena L de Figueiredo-Pontes, Susumu Kobayashi, Daniel B Costa. J Thorac Oncol 2012
100
Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
Mariacarmela Santarpia, Giuseppe Altavilla, Rafael Rosell. Expert Rev Respir Med 2015
Mariacarmela Santarpia, Giuseppe Altavilla, Rafael Rosell. Expert Rev Respir Med 2015
100
Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
Paola Bordi, Marcello Tiseo, Eleonora Rofi, Iacopo Petrini, Giuliana Restante, Romano Danesi, Marzia Del Re. Clin Lung Cancer 2017
Paola Bordi, Marcello Tiseo, Eleonora Rofi, Iacopo Petrini, Giuliana Restante, Romano Danesi, Marzia Del Re. Clin Lung Cancer 2017
100
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
Alice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, Subba R Digumarthy, Daniel B Costa, Rebecca S Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott,[...]. J Clin Oncol 2009
100
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang,[...]. Lancet Respir Med 2020
Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang,[...]. Lancet Respir Med 2020
100
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
Justin F Gainor, Leila Dardaei, Satoshi Yoda, Luc Friboulet, Ignaty Leshchiner, Ryohei Katayama, Ibiayi Dagogo-Jack, Shirish Gadgeel, Katherine Schultz, Manrose Singh,[...]. Cancer Discov 2016
100
Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells.
Koh Furugaki, Naoki Harada, Yasushi Yoshimura. Anticancer Drugs 2022
Koh Furugaki, Naoki Harada, Yasushi Yoshimura. Anticancer Drugs 2022
100
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Zong-Jun Xia, Yin-Chun Ji, De-Qiao Sun, Xia Peng, Ying-Lei Gao, Yan-Fen Fang, Xing-Dong Zhao, Wei-Bo Wang, Jian Ding, Mei-Yu Geng,[...]. Acta Pharmacol Sin 2021
Zong-Jun Xia, Yin-Chun Ji, De-Qiao Sun, Xia Peng, Ying-Lei Gao, Yan-Fen Fang, Xing-Dong Zhao, Wei-Bo Wang, Jian Ding, Mei-Yu Geng,[...]. Acta Pharmacol Sin 2021
100
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer.
Roxana Reyes, Noemi Reguart. Transl Lung Cancer Res 2021
Roxana Reyes, Noemi Reguart. Transl Lung Cancer Res 2021
100
Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Yingming Wang, Lingfei Han, Fulei Liu, Fubai Yang, Xueyang Jiang, Haopeng Sun, Feng Feng, Jingwei Xue, Wenyuan Liu. Colloids Surf B Biointerfaces 2020
Yingming Wang, Lingfei Han, Fulei Liu, Fubai Yang, Xueyang Jiang, Haopeng Sun, Feng Feng, Jingwei Xue, Wenyuan Liu. Colloids Surf B Biointerfaces 2020
100
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Alice T Shaw, Luc Friboulet, Ignaty Leshchiner, Justin F Gainor, Simon Bergqvist, Alexei Brooun, Benjamin J Burke, Ya-Li Deng, Wei Liu, Leila Dardaei,[...]. N Engl J Med 2016
Alice T Shaw, Luc Friboulet, Ignaty Leshchiner, Justin F Gainor, Simon Bergqvist, Alexei Brooun, Benjamin J Burke, Ya-Li Deng, Wei Liu, Leila Dardaei,[...]. N Engl J Med 2016
100
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.
Erin Larkins, Gideon M Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney Helms,[...]. Clin Cancer Res 2016
Erin Larkins, Gideon M Blumenthal, Huanyu Chen, Kun He, Rajiv Agarwal, Gerlie Gieser, Olen Stephens, Eias Zahalka, Kimberly Ringgold, Whitney Helms,[...]. Clin Cancer Res 2016
100
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, Takaaki A Fukami, Nobuhiro Oikawa, Takuo Tsukuda, Nobuya Ishii, Yuko Aoki. Cancer Cell 2011
Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, Takaaki A Fukami, Nobuhiro Oikawa, Takuo Tsukuda, Nobuya Ishii, Yuko Aoki. Cancer Cell 2011
100
Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.
Joanna Roopkumar, Shyam K Poudel, Lorenzo Gervaso, Chandana A Reddy, Vamsidhar Velcheti, Nathan A Pennell, Keith R McCrae, Alok A Khorana. J Thromb Haemost 2021
Joanna Roopkumar, Shyam K Poudel, Lorenzo Gervaso, Chandana A Reddy, Vamsidhar Velcheti, Nathan A Pennell, Keith R McCrae, Alok A Khorana. J Thromb Haemost 2021
100
Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello. Crit Rev Oncol Hematol 2018
Alfredo Addeo, Fabrizio Tabbò, Tim Robinson, Lucio Buffoni, Silvia Novello. Crit Rev Oncol Hematol 2018
100
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.
Jessica J Lin, Ginger Y Jiang, Nencyben Joshipura, Jennifer Ackil, Subba R Digumarthy, Sandra P Rincon, Beow Y Yeap, Justin F Gainor, Alice T Shaw. J Thorac Oncol 2019
Jessica J Lin, Ginger Y Jiang, Nencyben Joshipura, Jennifer Ackil, Subba R Digumarthy, Sandra P Rincon, Beow Y Yeap, Justin F Gainor, Alice T Shaw. J Thorac Oncol 2019
100
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Noriko Yanagitani, Ken Uchibori, Sumie Koike, Mika Tsukahara, Satoru Kitazono, Takahiro Yoshizawa, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Tambo, Shingo Nishikawa,[...]. Cancer Sci 2020
Noriko Yanagitani, Ken Uchibori, Sumie Koike, Mika Tsukahara, Satoru Kitazono, Takahiro Yoshizawa, Atsushi Horiike, Fumiyoshi Ohyanagi, Yuichi Tambo, Shingo Nishikawa,[...]. Cancer Sci 2020
100
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, Benjamin J Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski,[...]. Cancer Discov 2018
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, Benjamin J Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski,[...]. Cancer Discov 2018
100
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet,[...]. Lancet Oncol 2020
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet,[...]. Lancet Oncol 2020
100
Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study.
Ziwei Huang, Qi Xiong, Zhi Cui, Haitao Tao, Sujie Zhang, Lijie Wang, Pengfei Cui, Shixue Chen, Di Huang, Bo Yang,[...]. Am J Transl Res 2021
Ziwei Huang, Qi Xiong, Zhi Cui, Haitao Tao, Sujie Zhang, Lijie Wang, Pengfei Cui, Shixue Chen, Di Huang, Bo Yang,[...]. Am J Transl Res 2021
100
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
Kimberly L Johung, Norman Yeh, Neil B Desai, Terence M Williams, Tim Lautenschlaeger, Nils D Arvold, Matthew S Ning, Albert Attia, Christine M Lovly, Sarah Goldberg,[...]. J Clin Oncol 2016
Kimberly L Johung, Norman Yeh, Neil B Desai, Terence M Williams, Tim Lautenschlaeger, Nils D Arvold, Matthew S Ning, Albert Attia, Christine M Lovly, Sarah Goldberg,[...]. J Clin Oncol 2016
100
Emerging Roles of ALK in Immunity and Insights for Immunotherapy.
Lan Wang, Vivian Wai Yan Lui. Cancers (Basel) 2020
Lan Wang, Vivian Wai Yan Lui. Cancers (Basel) 2020
100
Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis.
Koichi Ando, Kaho Akimoto, Hiroki Sato, Ryo Manabe, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori,[...]. Cancers (Basel) 2020
Koichi Ando, Kaho Akimoto, Hiroki Sato, Ryo Manabe, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori,[...]. Cancers (Basel) 2020
100
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.
Mi Ran Yun, Sun Min Lim, Seon-Kyu Kim, Hun Mi Choi, Kyoung-Ho Pyo, Seong Keun Kim, Ji Min Lee, You Won Lee, Jae Woo Choi, Hye Ryun Kim,[...]. Cancer Res 2018
Mi Ran Yun, Sun Min Lim, Seon-Kyu Kim, Hun Mi Choi, Kyoung-Ho Pyo, Seong Keun Kim, Ji Min Lee, You Won Lee, Jae Woo Choi, Hye Ryun Kim,[...]. Cancer Res 2018
100
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec,[...]. Clin Cancer Res 2020
Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z Rizvi, Rosa L Frias, Jean Paul Thiery, Jean-Yves Scoazec,[...]. Clin Cancer Res 2020
100
Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.
Richard Bayliss, Jene Choi, Dean A Fennell, Andrew M Fry, Mark W Richards. Cell Mol Life Sci 2016
Richard Bayliss, Jene Choi, Dean A Fennell, Andrew M Fry, Mark W Richards. Cell Mol Life Sci 2016
100
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.
Ling Peng, Dafeng Lu, Yang Xia, Shaodong Hong, Giovanni Selvaggi, Justin Stebbing, Yilan Sun, Fei Liang. Front Oncol 2021
Ling Peng, Dafeng Lu, Yang Xia, Shaodong Hong, Giovanni Selvaggi, Justin Stebbing, Yilan Sun, Fei Liang. Front Oncol 2021
100
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer.
Jin Kang, Xu-Chao Zhang, Hua-Jun Chen, Wen-Zhao Zhong, Yang Xu, Jian Su, Qing Zhou, Hai-Yan Tu, Zhen Wang, Chong-Rui Xu,[...]. Front Oncol 2020
Jin Kang, Xu-Chao Zhang, Hua-Jun Chen, Wen-Zhao Zhong, Yang Xu, Jian Su, Qing Zhou, Hai-Yan Tu, Zhen Wang, Chong-Rui Xu,[...]. Front Oncol 2020
100
Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
Peter N Morcos, Eveline Nueesch, Felix Jaminion, Elena Guerini, Joy C Hsu, Walter Bordogna, Bogdana Balas, Francois Mercier. Cancer Chemother Pharmacol 2018
Peter N Morcos, Eveline Nueesch, Felix Jaminion, Elena Guerini, Joy C Hsu, Walter Bordogna, Bogdana Balas, Francois Mercier. Cancer Chemother Pharmacol 2018
100
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.